{"product_id":"gilead-five-forces-analysis","title":"Gilead Sciences Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGilead Sciences operates in a high-stakes biotech landscape where buyer power, supplier constraints, regulatory barriers, and intense rivalry shape margins and innovation incentives; patent cliffs and generics heighten substitute threats while M\u0026amp;A and scale raise entry barriers.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Gilead Sciences’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized API Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead depends on a small set of specialized API makers for complex antivirals and oncology drugs; industry data shows top-tier API suppliers control roughly 60–70% of capacity for key intermediates as of 2025. \u003c\/p\u003e\n\u003cp\u003eThese qualified vendors must meet strict purity and safety standards, so Gilead faces higher switching costs and validation times (often 9–18 months), raising supplier leverage. \u003c\/p\u003e\n\u003cp\u003eAs a result, suppliers hold pricing power in long-term contracts, contributing to input-cost volatility that can shift gross margins by 100–300 basis points annually. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research and Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGilead increasingly uses CROs and CMOs for trials and large-scale manufacturing to stay agile, with third parties accounting for an estimated 40–60% of its external manufacturing spend in 2024; these suppliers hold leverage via specialized bioprocess infrastructure and tacit know-how, and moving work can cost tens of millions plus 6–18 months for tech transfer and regulatory re-validation, risking trial delays and lost revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property for Platform Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs Gilead expands into cell therapy and oncology, smaller biotech and academic licensors hold strong bargaining power because their patented platform technologies are often indispensable; in 2024 Gilead disclosed over 30 platform licenses worth an estimated $1.2–1.6 billion in upfront and milestone commitments, showing material supplier leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Compliance Standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers must meet FDA Good Manufacturing Practice (GMP) and comparable EMA\/PMDA rules, which in 2024 led to ~12% of global drug‑ingredient firms holding full GMP certification, shrinking Gilead’s vetted supplier pool.\u003c\/p\u003e\n\u003cp\u003eThis regulatory scarcity raises supplier leverage: in 2023 supplier-related delays contributed to ~3–5% revenue at‑risk across large biotech peers, so Gilead faces higher switching costs and price sensitivity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP-certified suppliers ≈12%\u003c\/li\u003e\n\u003cli\u003ePeer revenue at‑risk from supplier delays 3–5% (2023)\u003c\/li\u003e\n\u003cli\u003eHigh switching cost, limited backup vendors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Switching Costs for Validated Inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHigh switching costs: once a Gilead drug’s manufacturing process is approved, changing raw-material suppliers triggers multi-year revalidation, regulatory filings, and stability studies, creating supplier lock-in.\u003c\/p\u003e\n\u003cp\u003eSuppliers exploit this: long-term contracts and limited alternatives let suppliers raise prices; Gilead reported 2024 COGS (cost of goods sold) of $6.8B, so even small supplier price hikes materially affect margins.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: a 1% supplier price increase on $6.8B adds $68M annual cost; requalifying a new supplier can take 18–36 months and cost millions in testing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory revalidation: 18–36 months\u003c\/li\u003e\n\u003cli\u003e2024 COGS impact: $6.8B; 1% = $68M\u003c\/li\u003e\n\u003cli\u003eSupplier leverage: higher due to few validated sources\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration risks: Gilead’s API\/GMP bottlenecks threaten margins ($68M\/1%)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGilead faces strong supplier power: ~60–70% of API capacity concentrated among top vendors (2025), only ~12% of firms hold full GMP (2024), and CRO\/CMO reliance was ~40–60% of external manufacturing spend (2024), raising switching costs (9–36 months) and margin sensitivity (2024 COGS $6.8B; 1% = $68M).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-tier API capacity (2025)\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP-certified suppliers (2024)\u003c\/td\u003e\n\u003ctd\u003e≈12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CMO share of external spend (2024)\u003c\/td\u003e\n\u003ctd\u003e40–60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS (2024)\u003c\/td\u003e\n\u003ctd\u003e$6.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRequalification time\u003c\/td\u003e\n\u003ctd\u003e9–36 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Gilead Sciences that uncovers competitive pressures, supplier and buyer influence, threats from substitutes and new entrants, and strategic barriers protecting its biopharma market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces summary for Gilead—clarifying competitive intensity, supplier\/customer leverage, threat of substitutes\/entrants, and regulatory pressure for rapid strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Reimbursement and Price Negotiations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act (2022) lets Medicare negotiate prices for selected drugs, strengthening government payers' bargaining power; since Medicare and Medicaid accounted for about 40% of Gilead Sciences' U.S. revenues in 2023, negotiated cuts for top sellers like Biktarvy and Veklury could shave percentage points off margins. This shifts the sector toward buyer-led pricing and raises downside risk to Gilead’s EBITDA and free cash flow forecasts for 2025–27.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa small number of large pharmacy benefit managers control formularies covering roughly us commercially insured lives giving them strong leverage over gilead sciences they extract rebates often exceeding list price for preferred placement. if a product is excluded from major pbm it can lose tens millions in annual sales immediately example formulary exclusion could cut drug accessible market by consolidation thus raises bargaining costs and compresses net margins.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital System Procurement Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospital system consolidation now means the top 25 US health systems accounted for about 45% of inpatient beds in 2024, letting them secure bulk purchasing and steer contracts for oncology and acute-care drugs.\u003c\/p\u003e\n\u003cp\u003eFor Gilead Sciences, buyers with high volume pushed average discount pressure of 15–25% on inpatient biologics in 2024, forcing more price concessions and rebate deals.\u003c\/p\u003e\n\u003cp\u003eThese systems demand value-based outcomes, so Gilead competes increasingly on demonstrated real-world effectiveness and contract terms tied to patient survival and readmission metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Organizations and Non-Profits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpin hiv and hepatitis markets global fund ngos buy at scale for low-income countries forcing gilead into tiered pricing that can cut per-unit revenue by versus high-income prices in reported low emerging antiviral sales. these buyers control access procurement so their cost-effectiveness demands strongly shape international volume strategies.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal Fund\/NGO gatekeeper role: high influence\u003c\/li\u003e\n\u003cli\u003eTiered pricing: cuts 40–70% per-unit price\u003c\/li\u003e\n\u003cli\u003e2024 antiviral emerging-market sales ≈ $2.1B\u003c\/li\u003e\n\u003cli\u003eVolume access traded for low margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pin\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Public Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups and calls for pricing transparency force Gilead to justify high prices, with 2024 polls showing 68% of US respondents support caps on drug prices and 42 US states considering transparency laws.\u003c\/p\u003e\n\u003cp\u003eThese groups sway policy and public opinion, contributing to measures like compulsory licensing discussions in India and EU scrutiny that limit Gilead’s ability to maintain premium pricing for therapies such as Biktarvy and Veklury.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% US public support price caps (2024 poll)\u003c\/li\u003e\n\u003cli\u003e42 US states considered transparency laws (2024)\u003c\/li\u003e\n\u003cli\u003eCompulsory licensing debated in India, EU scrutiny ongoing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers wield pricing power: Medicare, PBMs, hospitals \u0026amp; NGOs force 15–70% cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold strong leverage: Medicare\/Medicaid ~40% of US revenue (2023) enables negotiated cuts under IRA; PBMs cover ~85% of commercially insured lives extracting 20–40%+ rebates; top 25 health systems = 45% inpatient beds (2024) press 15–25% discounts on biologics; Global Fund\/NGOs force 40–70% tiered-price cuts (Gilead ~$2.1B emerging‑market antiviral sales, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023–24\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\/Medicaid\u003c\/td\u003e\n\u003ctd\u003eShare of US revenue\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBMs\u003c\/td\u003e\n\u003ctd\u003eCoverage of commercial lives\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop health systems\u003c\/td\u003e\n\u003ctd\u003eInpatient beds share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscount pressure\u003c\/td\u003e\n\u003ctd\u003eOn biologics\u003c\/td\u003e\n\u003ctd\u003e15–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGO tiering\u003c\/td\u003e\n\u003ctd\u003ePrice cut vs high‑income\u003c\/td\u003e\n\u003ctd\u003e40–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilead EM antivirals\u003c\/td\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003e$2.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eGilead Sciences Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Gilead Sciences Porter’s Five Forces analysis you’ll receive immediately after purchase—no placeholders or mockups. The document covers supplier and buyer power, competitive rivalry, threat of substitutes, and barriers to entry with actionable insights. It’s fully formatted, professionally written, and ready for instant download. What you see is the deliverable you’ll get upon payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747044209017,"sku":"gilead-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/gilead-five-forces-analysis.png?v=1772194548","url":"https:\/\/matrixbcg.com\/products\/gilead-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}